Depression News and Research

Latest Depression News and Research

Transcendental Meditation may be effective in reducing BP and psychological distress

"The Transcendental Meditation Program, a widely-used standardized program to reduce stress, showed significant decreases in blood pressure and improved mental health in young adults at risk for hypertension," said David Haaga, PhD, co-author of the study and professor of psychology at American University in Washington, D.C.

18 Nov 2009

Family caregivers can reduce suffering in cancer patients through simple touch and massage techniques

Family caregivers can significantly reduce suffering in cancer patients at home through use of simple touch and massage techniques. These findings were recently reported at the 6th International Conference of the Society for Integrative Oncology.

18 Nov 2009

Depression is as much of a risk factor for mortality as smoking, says new study

A study by researchers at the University of Bergen, Norway, and the Institute of Psychiatry (IoP) at King's College London has found that depression is as much of a risk factor for mortality as smoking.

17 Nov 2009

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

An alliance of institutions collectively managing an estimated 80 percent of all public health research funding worldwide today announced their first targets for concerted action in the fight against "chronic non-communicable diseases" (CNCDs).

17 Nov 2009

Telephone-delivered collaborative care for treatment of depression in post-CABG patients improve outcomes

Patients who received telephone-delivered collaborative care for treatment of depression after coronary artery bypass graft surgery reported greater improvement in measures of quality of life, physical functioning and mood than patients who received usual care, according to a study in the November 18 issue of JAMA. The study is being released early online because of its presentation at an American Heart Association scientific conference.

17 Nov 2009

Improved productivity and lowered absenteeism are top priorities for business leaders

Improving productivity by keeping employees healthy and working is emerging as the top business objective for employer-sponsored wellness programs around the world. The two exceptions are the United States, where reducing health care cost increases overwhelmingly continues to be the top goal, and Asia, where the most important objective is improving workforce morale.

17 Nov 2009

Studies reveal link between parental monitoring and decreased marijuana usage in adolescents

Marijuana is the most widely used illicit drug by adolescents, with almost 42% of high school seniors admitting to having experimented with it. Continued marijuana use may result in a number of serious consequences including depression, cognitive impairment, cardiovascular disease, and certain forms of cancer.

17 Nov 2009

FDA approves Par Pharmaceutical's new painkiller drug

Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for the 100mg and 200mg strengths of tramadol ER.

17 Nov 2009

Eisai's LUSEDRA Injection now available for MAC sedation

Eisai Inc. today announced that LUSEDRA(TM) (fospropofol disodium) Injection is now available for use by persons trained in the administration of general anesthesia. LUSEDRA, an aqueous solution, is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.

16 Nov 2009

Cortex Pharmaceuticals reports a net loss of $0.06 per share for the quarter ended September 30, 2009

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of $3,243,000, or $0.06 per share for the quarter ended September 30, 2009 compared with a net loss applicable to common stock of $3,148,000, or $0.07 per share for the corresponding prior year period.

16 Nov 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).

16 Nov 2009

Positive results from Winston Laboratories' Civamide Patch trial

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced positive top-line results from Study WL1001-04-03, a Phase II clinical trial evaluating the safety and efficacy of the company's patch formulation of Civamide, a novel TRPV-1 receptor modulator in the treatment of post-herpetic neuralgia (PHN).

16 Nov 2009

Self-care tips for hemorrhoids from Mayo Clinic

By about age 50, more than half of adults have dealt with hemorrhoids. The November issue of Mayo Clinic Health Letter covers home treatments that can relieve symptoms of this common and embarrassing problem.

16 Nov 2009

HealthPartners' health plans ranked top in Minnesota

HealthPartners is among the top 25 best private health plans in the nation and the top ranked plan in Minnesota according to U.S. News & World Report/NCQA “America's Best Health Insurance Plans 2009-10.” The report measures how well health plans perform on 50 measures of health care and member satisfaction. Two hundred thirty nine health plans from across the nation are included in the report. The top 50 health plans, including HealthPartners, are listed in the Nov. 16, 2009 print edition of U.S. News & World Report.

16 Nov 2009

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

16 Nov 2009

Chronic pain patients with depression three times more likely to receive opioid medications

Chronic pain patients with a history of depression are three times more likely to receive long-term prescriptions for opioid medications like Vicodin compared to pain patients who do not suffer from depression, according to new research.

16 Nov 2009

Poor mental health in children and teenagers impacts on the length of time they will stay in school: Study

"Our study shows that poor mental health in children and teenagers has a large impact on the length of time they will stay in school," says Dr. Lehrer. He notes a large number of school-based programs have recently been introduced to prevent childhood obesity through lifestyle changes, but suggests the net should be cast more widely. "It's important for policymakers to target health conditions that are not the easiest to identify - like inattention - but may have larger impacts on one's future."

13 Nov 2009

Shire announces findings from Phase 3 study data with Vyvanse

Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

13 Nov 2009

PKCI/HINT1 gene associated with mood regulation

Removing the PKCI/HINT1 gene from mice has an anti-depressant-like and anxiolytic-like effect. Researchers writing in the open access journal BMC Neuroscience applied a battery of behavioral tests to the PKCI/HINT1 knockout animals, concluding that the deleted gene may have an important role in mood regulation.

13 Nov 2009

Health Canada approves ONGLYZA for type 2 diabetes treatment

Bristol-Myers Squibb Canada and AstraZeneca Canada today announced that Health Canada has approved ONGLYZA(TM) (saxagliptin) which improves all three key measures of glycemic control - hemoglobin A1c (A1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG) - when taken in combination with other commonly used oral anti-diabetic agents (metformin or a sulfonylurea).

13 Nov 2009

Depression News and Research

Latest Depression News and Research

Transcendental Meditation may be effective in reducing BP and psychological distress

Family caregivers can reduce suffering in cancer patients through simple touch and massage techniques

Depression is as much of a risk factor for mortality as smoking, says new study

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

Telephone-delivered collaborative care for treatment of depression in post-CABG patients improve outcomes

Improved productivity and lowered absenteeism are top priorities for business leaders

Studies reveal link between parental monitoring and decreased marijuana usage in adolescents

FDA approves Par Pharmaceutical's new painkiller drug

Eisai's LUSEDRA Injection now available for MAC sedation

Cortex Pharmaceuticals reports a net loss of $0.06 per share for the quarter ended September 30, 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Positive results from Winston Laboratories' Civamide Patch trial

Self-care tips for hemorrhoids from Mayo Clinic

HealthPartners' health plans ranked top in Minnesota

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Chronic pain patients with depression three times more likely to receive opioid medications

Poor mental health in children and teenagers impacts on the length of time they will stay in school: Study

Shire announces findings from Phase 3 study data with Vyvanse

PKCI/HINT1 gene associated with mood regulation

Health Canada approves ONGLYZA for type 2 diabetes treatment

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Depression News and Research

Latest Depression News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in